[go: up one dir, main page]

MA31776B1 - Composé inhibiteur de la glycogène phosphorylase et composition pharmaceutique contenant ledit composé - Google Patents

Composé inhibiteur de la glycogène phosphorylase et composition pharmaceutique contenant ledit composé

Info

Publication number
MA31776B1
MA31776B1 MA32771A MA32771A MA31776B1 MA 31776 B1 MA31776 B1 MA 31776B1 MA 32771 A MA32771 A MA 32771A MA 32771 A MA32771 A MA 32771A MA 31776 B1 MA31776 B1 MA 31776B1
Authority
MA
Morocco
Prior art keywords
compound
pharmaceutical composition
glycogen phosphorylase
phosphorylase inhibiting
inhibiting compound
Prior art date
Application number
MA32771A
Other languages
Arabic (ar)
English (en)
Inventor
Pierette Banker
Eric Eugene Boros
Scott Howard Dickerson
Istvan Kaldor
Cecilia S Koble
Michael Tolar Martin
Steven Meagher Sparks
Stephen Andrew Thomson
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of MA31776B1 publication Critical patent/MA31776B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/32—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms
    • C07C275/34—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms having nitrogen atoms of urea groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne un nouveau composé qui est un inhibiteur de la glycogène phosphorylase et son utilisation pour traiter le diabète et d'autres états associés à ce dernier. L'invention concerne également une composition pharmaceutique contenant ledit composé et des procédés pour préparer le composé et la composition pharmaceutique.
MA32771A 2007-09-28 2010-04-14 Composé inhibiteur de la glycogène phosphorylase et composition pharmaceutique contenant ledit composé MA31776B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97586207P 2007-09-28 2007-09-28
PCT/US2008/077624 WO2009045830A1 (fr) 2007-09-28 2008-09-25 Composé inhibiteur de la glycogène phosphorylase et composition pharmaceutique contenant ledit composé

Publications (1)

Publication Number Publication Date
MA31776B1 true MA31776B1 (fr) 2010-10-01

Family

ID=40098462

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32771A MA31776B1 (fr) 2007-09-28 2010-04-14 Composé inhibiteur de la glycogène phosphorylase et composition pharmaceutique contenant ledit composé

Country Status (16)

Country Link
US (1) US20100305207A1 (fr)
EP (1) EP2195287A1 (fr)
JP (1) JP2010540552A (fr)
KR (1) KR20100087300A (fr)
CN (1) CN101932557A (fr)
AU (1) AU2008309003A1 (fr)
BR (1) BRPI0817721A2 (fr)
CA (1) CA2701120A1 (fr)
CO (1) CO6270306A2 (fr)
CR (1) CR11398A (fr)
DO (1) DOP2010000075A (fr)
EA (1) EA201000391A1 (fr)
MA (1) MA31776B1 (fr)
MX (1) MX2010003440A (fr)
WO (1) WO2009045830A1 (fr)
ZA (1) ZA201002181B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011107494A1 (fr) 2010-03-03 2011-09-09 Sanofi Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
EP2738163B1 (fr) 2011-07-29 2016-01-20 Taisho Pharmaceutical Co., Ltd. Composé d'amidine ou sel de celui-ci
WO2013037390A1 (fr) 2011-09-12 2013-03-21 Sanofi Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
EP2760862B1 (fr) 2011-09-27 2015-10-21 Sanofi Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
JP7307440B2 (ja) * 2019-12-06 2023-07-12 エスケイシー・カンパニー・リミテッド 光学レンズ用ジイソシアネート組成物およびその調製方法
WO2021122645A1 (fr) 2019-12-20 2021-06-24 Syngenta Crop Protection Ag Composés azole-amide à action pesticide

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11503110A (ja) * 1995-02-17 1999-03-23 スミスクライン・ビーチャム・コーポレイション Ｉｌ−８受容体拮抗剤
SK66798A3 (en) * 1995-11-24 1999-01-11 Smithkline Beecham Spa Quinoline derivative, preparation method thereof, pharmaceutical composition containing the same and its use
CA2255858C (fr) * 1996-05-24 2007-09-11 Neurosearch A/S Derives phenyle contenant un groupe acide, leur preparation et leur utilisation comme inhibiteurs des vannes a chlorure
AU2003258491A1 (en) * 2002-09-05 2004-03-29 Neurosearch A/S Amide derivatives and their use as chloride channel blockers
ES2327834T3 (es) * 2002-11-21 2009-11-04 Neurosearch A/S Derivados de diarilureido y su uso medico.
MX2007005590A (es) * 2004-11-09 2007-05-24 Smithkline Beecham Corp Compuestos del inhibidor glicogeno fosforilasa y sus composiciones farmaceuticas.

Also Published As

Publication number Publication date
JP2010540552A (ja) 2010-12-24
BRPI0817721A2 (pt) 2015-03-31
CA2701120A1 (fr) 2009-04-09
MX2010003440A (es) 2010-04-21
CR11398A (es) 2010-06-28
WO2009045830A1 (fr) 2009-04-09
EA201000391A1 (ru) 2010-10-29
CO6270306A2 (es) 2011-04-20
KR20100087300A (ko) 2010-08-04
DOP2010000075A (es) 2010-07-15
EP2195287A1 (fr) 2010-06-16
CN101932557A (zh) 2010-12-29
US20100305207A1 (en) 2010-12-02
ZA201002181B (en) 2011-06-29
AU2008309003A1 (en) 2009-04-09

Similar Documents

Publication Publication Date Title
MA31776B1 (fr) Composé inhibiteur de la glycogène phosphorylase et composition pharmaceutique contenant ledit composé
MA31775B1 (fr) Composé inhibiteur de la glycogène phosphorylase et composition pharmaceutique contenant ledit composé
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
WO2001081310A8 (fr) 1-aroyle-piperidinyle benzamidines
GEP20125506B (en) Glucagon receptor antagonist compounds, compositions containing such compounds and use
EA200800415A1 (ru) Удаление пероксида из носителя для доставки лекарственного средства
MX2009000285A (es) Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas.
TN2009000059A1 (fr) Formes de dosage pharmaceutiques orales anti-manipulation contenant un analgesique opioide
MX2009000657A (es) Composiciones y metodos para el tratamiento de mucositis.
CL2011001082A1 (es) Compuestos derivados de amino-tetrahidropiranos sustituidos con heterociclos, composicion farmaceutica; y uso en el tratamiento de una afeccion seleccionada de resistencia a la insulina, hiperglicemia y diabetes de tipo 2.
UA109036C2 (en) COMPOSITION CONTAINING FUNGICIDUM STRAIN AND CHEMICAL COMPOUND
MX2009003821A (es) Compuestos de n-aril pirazol para usarse contra la diabetes.
PT1984357E (pt) Compostos de 2,4-pirimidinadiamina para tratamento ou prevenção de doenças autoimunes
EA200870472A1 (ru) Ингибиторы 11-бета-гидроксистероид-дегидрогеназы типа 1
TW200740799A (en) Alpha2C adrenoreceptor agonists
PH12013500913A1 (en) Substituted-quinoxaline-type-piperidine compounds and the uses thereof
MA35404B1 (fr) Composés pour le traitement de la toxicomanie
WO2008013840A3 (fr) Analogues de l'érastine et leurs utilisations
TNSN07383A1 (en) 1-h-quinazoline-2,4-diones and their use as ampa-receptor ligands
GEP20135929B (en) Compositions containing asphalt
GEP20084361B (en) Piperidinylcarbonyl-pyrro-lidines and their use as melanocortin agonists
MA32061B1 (fr) Triazolopyridazines en tant qu'inhibiteurs de par1, production de celles-ci, et utilisation en tant que médicaments
EA200600590A1 (ru) Фармацевтические композиции модафинила с модифицированным высвобождением
MA28093A1 (fr) Forme polymorphe de 3-phenylsulfonyl-8-piperazine-1-yl-quinoleine
DE602007007934D1 (en) Imidazoazephinonverbindungen